News Feed

ImmunoPrecise Announces Expansion into Humanizing Technologies

 

ImmunoPrecise Antibodies announced that they have completed significant steps that enhance its ability to deliver humanized monoclonal antibodies to customers.

ImmunoPrecise has conducted research and development activities using transgenic mice and rats to successfully deliver humanized monoclonal antibodies to drug development companies this past quarter. Importantly, these projects served to demonstrate the value of applying the Company’s proprietary Rapid Prime methodology in transgenic animals.

“We are very pleased with the success of our Rapid Prime methodology in these animals,” said Teri Otto, Head of Laboratory Services at ImmunoPrecise. “We delivered a large number of high-quality clones to our customers in a short time frame. It is extremely important to emphasize that our consistent high quality and superior speed is crucial to the clientele we serve and one of the keys to unlocking new and repeat business.”

In addition, ImmunoPrecise has begun collaborating with companies that provide next generation sequencing. Next generation sequencing allows scientists to take a rabbit monoclonal antibody generated by ImmunoPrecise, use powerful bioinformatics to compare its sequence to a human antibody reference library, and then genetically engineer it to be more human-like. ImmunoPrecise’s goal is to continue working with companies providing humanizing platforms based on transgenic animals as well as collaborate with companies applying bioinformatics in humanization. These strategies will allow ImmunoPrecise to offer clients a broad choice of potential humanizing solutions.

Thomas D’Orazio, President and CEO of ImmunoPrecise stated,

“The introduction of these new technologies further expands ImmunoPrecise’s commercial and research and development activities in the humanizing space which is one of the Company’s key strategic growth initiatives,” Mr. D’Orazio explained. “The major advantage is that there are fewer contract research organizations (CROs) able to humanize antibodies due to intellectual property that limits market entry. Working with our customers and being able to offer more project specific solutions strengthens our relationships and further amplifies our capability to increase sales.”

Humanizing antibodies is a key step in developing monoclonal antibodies for human therapeutic use. Over 50% of all new drug therapies in development are antibody based. Leading pharmaceutical companies including Genentech, Bayer AG, Pfizer Inc., Sanofi, F. Hoffman-La Roche, Merck, GlaxoSmithKline, NovartisAG and Abbie and others have developed or are developing antibody based drug therapies including several of the top selling drugs in history. Transparency Market Research recently released a market study reporting that the monoclonal antibody therapeutic market will be worth $245 billion by 2024 up from $86.7 billion in 2015, representing a CAGR of 13.5%. Monoclonal antibodies are engineered to attach to specific proteins called antigens. They can work in a variety ways such as triggering an immune response, disrupting essential cell signaling, or used as conjugates that carry drugs directly to the diseased cells. Monoclonal antibodies have become a major source of blockbuster drugs. Examples include Humira (world’s top selling pharmaceutical product used for pain relief, $13 billion in 2014 global sales) and Avastin (an antibody based cancer drug that sold over $7.3 Billion in 2015).

To Top